Bio-Path Holdings Advances in RNAi Therapeutics with Promising Clinical Trials

Bio-Path Holdings, Inc., a clinical-stage biotechnology company, is making notable progress with its RNA interference (RNAi) therapeutics, leveraging its proprietary DNAbilize® platform. This technology, which enhances drug stability and cellular uptake while reducing toxicity, is at the heart of the company's innovative approach to treating complex diseases. With lead candidate prexigebersen (BP1001) in Phase 2 trials for acute myeloid leukemia (AML) and BP1001-A showing promise in Phase 1/1b trials for solid tumors and preclinical studies for obesity and type 2 diabetes, Bio-Path is at the forefront of developing targeted therapies.

The company's pipeline also includes BP1002, targeting the Bcl-2 protein for blood cancers and solid tumors, and BP1003, a STAT3 inhibitor aimed at pancreatic cancer, currently in preclinical development. The achievement of a third preclinical milestone for BP1001-A underscores its potential in addressing obesity in type 2 diabetes patients, a significant health challenge worldwide.

Bio-Path's strategic relationships, including its original technology platform licensed from The MD Anderson Cancer Center, and a strong intellectual property position, bolster its standing in the competitive biotechnology landscape. Despite a reported cash on hand of $122,000 as of March 31, 2025, and the need for additional funding to meet 2025 operational requirements, the company's undervaluation compared to peers highlights its growth potential. With numerous drug candidates in the pipeline and key milestones on the horizon, Bio-Path Holdings is poised to make a lasting impact on the treatment of cancers and metabolic diseases.